We understand that your project requires teamwork, know-how and experience. Our technology platform can fulfill your specific needs.

Our R&D technology innovation platform adheres to the concept of technology-driven innovation, providing customers with innovative solutions from the combination of synthesis, analysis, engineering and other aspects.

Based on the concept of green chemistry, Lianhe Aigen continues to introduce new process, equipment, and service concept, and continuously applies emerging technologies such as flow chemistry, enzyme catalysis, electrochemistry, and photochemistry to commercial production.

We are committed to providing integrated services for quality control at all stages of drug development, including drug development testing, preparative separation and purification, method development and validation, structural confirmation and impurity analysis, stability studies, filing material support services.

Our continuous flow processing capabilities offer unique advantages to perform chemistries difficult or impossible to do in the batch mode.

We provide systematic technical support for crystal form screening, crystallization and milling process development, test services to help customers shorten the filing time.

We design different protection strategies and cutting methods according to the different lengths and different synthesis scales of target peptides and the characteristics of different amino acids, and adopt solid phase, liquid phase or combination methods to effectively avoid impurities.

We are committed to providing diverse linker synthesis services for developing ADC/PROTAC drugs for innovative drug clients. We have experiences in delivering peptide, PEG, and other types of Linkers on gram to kilogram. At the same time, we can design and optimize the structure and synthesis route of linkers according to customer’s needs.

We have accumulated extensive experiences in modified nucleosides and nucleotides synthesis. Among them, phosphorylation reagents, ribose 2'-position modified monomers by fluorination or alkoxylation can be produced on a large scale. We have developed a stable and efficient production process for GalNAc, a nucleic acid drug delivery vehicle, with high yield and simple purification.